Introduction
Clopidogrel is a second-generation thienopyridine derivative used extensively as an orally administered antiplatelet agent. The use of clopidogrel has become standard treatment in patients with acute coronary syndromes and undergoing percutaneous coronary interventions.
Nevertheless, it has been consistently documented that a significant percentage (5-40%) of individuals treated with clopidogrel do not receive the anticipated therapeutic benefit, which in turn has been associated with an increased risk of adverse outcomes (Angiolillo et al., 2007; Karazniewicz-Lada et al., 2012) .
Clopidogrel is a prodrug which undergoes a complex metabolic scheme. It is initially absorbed in its inactive prodrug (parent) form, and after a multi-step biotransformation sequence in the liver, is ultimately metabolized to its active 5-thiol metabolite (Figure 1) . However, the majority of administered clopidogrel never enters this bioactivation cascade since ~ 85% of the absorbed prodrug is rapidly hydrolyzed to the inactive metabolite, clopidogrel carboxylic acid (Hagihara et al., 2009 ). This reaction is catalyzed by hepatic carboxylesterase 1 (CES1) (Tang et al., 2006) . Accordingly, only ~15% of a clopidogrel dose is available to undergo further oxidative metabolism catalyzed by cytochrome P450 (CYP) 1A2, 2B6, and 2C19, resulting in the formation of the thiolactone derivative, 2-oxo-clopidogrel. A portion 2-oxo-clopidogrel is then hydrolyzed by CES1 to form 2-oxo-clopidogrel carboxylate, an inactive metabolite, while the balance of 2-oxo-clopidogrel is further hydrolyzed to the unstable but active 5-thiol metabolite.
This final activation step is mediated by CYP2B6, CYP2C9, CYP2C19 and CYP3A4 (Kazui et al., 2010) . The 5-thiol clopidogrel active metabolite (clopidogrel-AM) is a labile bioreactive compound that forms a disulfide bridge that binds irreversibly to P2Y 12 receptors located on a J P E T # 2 0 1 6 4 0 6 platelet membrane causing irreversible blockade. Finally, CES1 again plays a role in the further hydrolysis of the clopidogrel-AM, ultimately forming the 5-thiol carboxylic acid metabolite (Bouman et al., 2011) .
With regard to formation of the clopidogrel-AM and its dependence on CYP enzymes, numerous studies have focused upon CYP2C19 and its functional variants such as the loss of or reduced function alleles *2, *3, *4,*5, *6, *7, *8 and the gain-of-function allele *17. Of these, CYP2C19*2 may have particular significance with regard to its influence on clopidogrel metabolism and ensuing pharmacokinetic and pharmacodynamic response (Mega et al., 2009; Shuldiner et al., 2009 ). However, CYP2C19*2 explains only 5-12% of the variability in clopidogrel response (Karazniewicz-Lada et al., 2012) , and the majority of therapeutic variability in clopidogrel treatment remains unknown.
In humans, CES1 is the most predominant hydrolytic enzyme, catalyzing the hydrolysis of numerous ester-and amide-containing endogenous compounds, toxins, and medications to their respective free acids (Imai et al., 2006; Ross and Crow, 2007) . CES1 contributes to 80%-95% of total hydrolytic activity in the human liver. Significant interindividual variability in the expression and activity of CES1 has been consistently observed and reported in the biomedical literature.
This variability is likely to be to the result of both genetic and environmental factors (Hosokawa et al., 1995; Fukami et al., 2008; Yoshimura et al., 2008; Yang et al., 2009; Zhu et al., 2009a; Shi et al., 2011; Ross et al., 2012) . We have reported that the CES1 single nucleotide polymorphisms (SNPs) G143E (rs71647871) and D260fs (rs71647872) exhibit markedly decreased enzymatic activity towards the hydrolysis of the CES1 substrates methylphenidate, oseltamivir, and trandolapril (Zhu et al., 2008; Zhu et al., 2009b; Zhu and Markowitz, 2009 
CES1 inhibition study in human liver s9 fractions
Pooled human liver s9 fractions were pre-incubated with an NADPH generating system (0.1 mg/ml yeast glucose-6-phosphate dehydrogenase, 3 mg/ml NADP+, and 0.07 M glucose-6-phosphate) in the presence and absence of the CES1 inhibitor BNPP at 37 ˚C for 5 min. The
reaction was initiated by adding clopidogrel. The final concentrations of the liver s9 fractions, BNPP, and clopidogrel in the reaction system were 4 mg/ml, 10 µM, and 20 µM, respectively, and the total volume was 200 µl. Samples (20 µl) were collected at 0.25, 0. between BNPP treated and untreated groups were compared using independent student t-test, and were considered statistically significant when p value was less than 0.05.
Establishment of cell lines stably expressing CES1 variants G18V, S82L, and A269S
The Flp-In TM -293 cell lines stably expressing wild type CES1 and its variants G143E and D260fs have been developed previously and applied to our ensuing CES1 pharmacogenetic studies (Zhu et al., 2008; Zhu et al., 2009b; Zhu and Markowitz, 2009 ). The minor allele frequency (MAF) of G143E is estimated to be 3.7%, 4.3%, 2.0%, and 0% in Caucasian, Blacks, Hispanic, and Asian populations, respectively, whereas D260fs appears to be a rare mutation in all racial and ethnic groups studied to date (Zhu et al., 2008) . In the present study, we developed three additional cell lines expressing the CES1 variants G18V (rs3826190), S82L (rs62028647), and A269S
(rs115629050) to study the effect of these nonsynonymous variants on CES1 enzymatic activity and clopidogrel hydrolysis. Briefly, the mutant CES1A1 plasmids were obtained via site-directed
mutagenesis assay using specific primers and probes. All plasmids were bidirectionally sequenced to confirm that the desired constructs were generated. The plasmids were cotransfected with the pOG44 plasmid at a ratio of 1:10 into Flp-In supernatant 9000 (s9) fractions, the cells were rinsed and suspended in PBS buffer solution (pH 7.4). The cells were then sonicated and the s9 fractions were collected after centrifugation at 9000g for 30 min at 4˚C. The protein concentration was determined using a Pierce BCA assay kit (Rockford, IL).
Hydrolysis of clopidogrel and 2-oxo-clopidogrel by wild type and mutant CES1
An in vitro incubation study was conducted to determine the catalytic activity of CES1 and its variants G18V, S82L, G143E, D260fs, A269S on the hydrolysis of clopidogrel and 2-oxo- for clopidogrel and 2-oxo-clopidogrel, respectively. The reaction was terminated by the addition of a 5-fold volume of acetonitrile containing the internal standard d4-clopidogrel (25 ng/ml).
After centrifugation at 16,000 ×g at 4 ˚C for 10 min, the supernatant was collected and analyzed for concentrations of the hydrolytic products (i.e. clopidogrel carboxylate and 2-oxo-clopidogrel carboxylate) utilizing established validated LC-MS/MS assay. Data were fit to the MichaelisMenten equation, and kinetic parameters K m and V max were calculated using nonlinear regression analysis (Graphpad Prism software Version 4.0 for Windows, Graphpad Software Inc., San Diego, CA). Additionally, in an effort to capture any substrate specificity exhibited by any variant, a well characterized CES1 selective substrate, methylphenidate was included in the incubation study at a single concentration of 100 µM. The experiment procedures were identical to those previously published (Zhu et al., 2008) . The catalytic activity of CES1 and its variants towards methylphenidate was evaluated by measuring the concentrations of the formed hydrolytic metabolite ritalinic acid.
HPLC-MS/MS assay
An HPLC-MS/MS assay was developed for the simultaneous quantification of clopidogrel and its five metabolites including the intermediate metabolite 2-oxo-clodipgrel, the active metabolite clopidogrel-AM, and three hydrolytic metabolites (i.e. clopidogrel carboxylate, 2-oxoclopidogrel carboxylate, and clopidogrel-AM carboxylate). This assay was a modification of a previously published method (Tuffal et al., 2011) . For the human liver s9 inhibition study, the samples were prepared by mixing 20 µl of reaction mixtures with 100 µl of acetonitrile containing the internal standard d4-clopidogrel (25 ng/ml) and the derivatizing agent MPB (5 mM). Clopidogrel-AM is very unstable, and thus was carefully derivatized with MPB to form the This article has not been copyedited and formatted. The final version may differ from this version. Tuffal et al., 2011) .
The mixtures were left standing at room temperature for 10 min to allow the derivatization reaction to proceed to completion. No derivatizing agent was used for the samples from the clopidogrel and 2-oxo-clopidogrel cell s9 hydrolysis studies. All samples were centrifuged at 16,000 ×g at 4ºC for 10 min to remove proteins. The resulting supernatant was then collected for HPLC-MS/MS analysis. As anticipated, two isomers of the thiol metabolites were observed (panel #4 from the top), which are Z compounds with reference to the C3-C16 double bond of 7S clopidogrel (Pereillo et al., 2002; Tuffal et al., 2011) . These two isomers differ in terms of whether the C4 configuration is R or S. After being separated by a conventional reverse-phase column (e.g. C18), the first and second peaks are noted to correspond to H3 and H4 metabolites, respectively (Tuffal et al., 2011) . It is essential that the analytical assay is enantioselective as both the H3 and H4 metabolites can be formed after hepatic metabolism, but only the H4 isomer is believed to be pharmacologically active. The identity of the active H4 metabolite was confirmed by performing comparisons with pure analytical reference standards.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results

BNPP affected clopidogrel metabolism and activation
Co-incubation of BNPP with human liver s9 fractions significantly increased the concentrations of clopidogrel, 2-oxo-clopidogrel, and clopidogrel-AM while the concentrations of all formed carboxylate metabolites were significantly decreased (Figure 2) . Notably, the AUC 0-22h of clopidogrel-AM increased by more than 100% in the presence of the CES1 inhibitor BNPP (Table 1 ). The ratios of clopidogrel to 2-oxo-clopidogrel and 2-oxo-clopidogrel to clopidogrel-AM were not increased following co-administration of BNPP, indicating the increased formation of clopidogrel-AM was not due to the interaction between BNPP and CYP isoenzymes. The data suggest that CES1 inhibition led to enhanced formation of clopidogrel-AM as well as the increased concentrations of the intermediate metabolite, 2-oxo-clopidogrel. .
The CES1 variants G143E and D260fs are loss-of-function variants for clopidogrel and 2-oxo-clopidogrel hydrolysis
Consistent with previous reports, both clopidogrel and 2-oxo-clopidogrel were efficiently hydrolyzed by wild type CES1 (Tang et al., 2006; Bouman et al., 2011) . The V max and K m values for clopidogrel were determined to be 3558 ± 371 pmol/min/mg protein and 62.7 ± 15.4 µM, respectively, while the V max and K m values for 2-oxo-clopidogrel were 158.1± 16.2 pmol/min/mg protein and 2.4 ± 0.6 µM, respectively. The enzymatic activity of the CES1 variants G143E and D260fs were completely impaired in terms of catalyzing the hydrolysis of clopidogrel and 2-oxoclopidogrel ( Figure 3 . The D260fs data overlapped with G143E, and are not shown in the Figure) . However, the variants G18V, S82L, and A269S produced no significant effect on CES1- clopidogrel, no catalytic activity of G143E or D260fs was observed with regard to methylphenidate metabolism, while the activity of G18V, S82L, and A269S appeared to remain intact and was comparable to that of wild type enzyme (Figure 4) . Thus, the study demonstrated that both 143E and D260fs are loss-of-function alleles and the G18V, S82L, and A269S are nonfunctional variants for all three tested CES1 substrates. The results also suggest that the commonly used in silico programs SIFT and Polyphen2 may not be useful approaches for the prediction of the function of CES1 nonsynonymous variants.
Discussion
CES1 is encoded in humans by the CES1 gene, which consists of three isoforms, i.e. CES1A1, CES1A2, and CES1A3 (Hosokawa et al., 2007; Fukami et al., 2008) . CES1A1 and CES1A3 are inversely located on chromosome 16 q13-q22.1 while CES1A2 is a variant of the CES1A3 gene (Fukami et al., 2008) . Both CES1A1 and CES1A2 are functional whereas CES1A3 is a pseudogene due to a premature stop codon located in exon 3 (Fukami et al., 2008; Zhu and Markowitz, 2012) . CES1A1 and CES1A2 are identical with the exception of the exon 1 and promoter regions. In the liver, the majority of CES1 is the product of the CES1A1 gene since the transcription efficiency of the CES1A2 gene is only ~ 2% of that of CES1A1, probably due to additional Sp1 and C/EBP binding sites in the promoter region of CES1A1 (Fukami et al., 2008; Hosokawa et al., 2008) . Thus, only CES1A1 genetic variants are likely to produce a significant impact on CES1 expression and activity.
CES1 expression and activity vary markedly among individuals. Consolidated evidence supports the presence of both genetic and non-genetic factors as significant contributors to observed variability (Hosokawa et al., 1995; Fukami et al., 2008; Yoshimura et al., 2008; Yang et al., 2009; Zhu et al., 2009a; Ross et al., 2012) . We have identified and characterized two novel CES1 nonsynonymous variants G143E and D260fs within the CES1A1 and CES1A2 genes, respectively, in a human subject participating in a normal volunteer pharmacokinetic study of dlmethylphenidate (Patrick et al., 2007; Zhu et al., 2008 blood pressure, mean arterial blood pressure, heart rate) in this poor metabolizer differed significantly from his study peers (Zhu et al., 2008 (Zhu et al., 2008; Zhu et al., 2009b; Zhu and Markowitz, 2009 ). Subsequently, a clinical study was conducted in patients with attention deficit-hyperactivity disorder (ADHD) treated with methylphenidate. The results showed that patients carrying the 143E allele required significantly lower doses of methylphenidate for symptom reduction relative to non-carriers (Nemoda et al., 2009) . These findings are consistent with the expectation that impaired hydrolysis of methylphenidate would result in higher systemic and CNS concentrations, and accordingly, a decreased need for upward dosage titration. Recently, and consistent with our published in vitro findings (Zhu and Markowitz, 2009 ), a healthy volunteer pharmacokinetic study demonstrated that the G143E variant significantly impaired the activation of the prodrug oseltamivir (Tarkiainen et al., 2012) . Notably, the AUC 0-∞ of oseltamivir in a homozygous variant type (143EE) was found to be 360% greater than the non-carrier peers.
Beyond the nonsynonymous SNPs, a number of SNPs within the promoter and 5'-untranslated region (5'-UTR) of CES1A1 and CES1A2/CES1A3 genes have been reported (Geshi et al., 2005; Yoshimura et al., 2008; Sai et al., 2010; Yamada et al., 2010) . Among them, -816A>C was reported to be significantly associated with the efficacy of the ACE inhibitor prodrug imidapril (Geshi et al., 2005) . However, a later study demonstrated that this SNP resides in the nonfunctional pseudogene CES1A3 (Sai et al., 2010) . Furthermore, it was not found to be associated with the activation of the partial CES1 substrate irinotecan, leaving its clinical significance unresolved (Sai et al., 2010) . Additionally, the variant -75T>G within the 5'-This article has not been copyedited and formatted. The final version may differ from this version. untranslated region (5'-UTR) of CES1A1 gene was recently found to be associated with isoniazid-induced hepatotoxicity in patients with latent tuberculosis . A subsequent clinical study revealed that the AUC ratios of irinotecan metabolites (SN-38+SN-38G) to irinotecan, an indicator of in vivo CES1 and CES2 activity, were significantly lower in cancer patients carrying the minor G allele relative to wild type patients (Sai et al., 2010) . Most recently, the -75G allele was associated with the worsening of appetite deduction in ADHD patients treated with methylphenidate (Bruxel et al., 2012) . In addition to the promoter, 5'-UTR, and nonsynonymous variants, more than 900 other CES1 variants, such as synonymous and intronic variants, have been documented in several SNP databases (e.g. NCBI dbSNP). However, the function of essentially none of these variants has been systematically evaluated to date.
Beyond the presence of functional CES1 variants, patient age and potential drug-drug interactions may contribute to interindividual variability in CES1 function as well. Data recently generated in our laboratory and by others demonstrate that the expression of CES1 is markedly lower in neonates and infants, gradually increases in a developmental manner, and full maturation in expression and function is observed by age 6 to 9 years (Yang et al., 2009; Zhu et al., 2009a; Shi et al., 2011) . Additionally, a number of commonly used medications have been recently identified as CES1 inhibitors or inducers Fukami et al., 2010; Zhu et al., 2010; Hatfield and Potter, 2011; Rhoades et al., 2012) . However, the magnitude of effect and clinical significance of CES1 inhibitors/inducers and developmental age need to be validated by in vivo assessments, and both areas of study are in their relative infancy.
CES1 is responsible for the initial hydrolysis of ~85% of clopidogrel, converting it to its inactive carboxylate metabolite, leaving a balance of ~15% of clopidogrel for further hepatic metabolism and D260fs exhibited null activity for the hydrolysis of both clopidogrel and 2-oxo-clopidogrel.
However, catalytic activity of the variants G18V, S82L, and A269S on the hydrolysis of clopidogrel or 2-oxo-clopidogrel was comparable to the wild type enzyme, indicating that these variants are nonfunctional SNPs for clopidogrel and 2-oxo-clopidogrel metabolism though all of these three variants were predicted to be potentially damaging to enzyme function by the in silico programs SIFT and Polyphen2. Clopidogrel-AM is very unstable, and is currently not commercially available. Thus, we were not able to evaluate whether these variants exert similar effects on clopidogrel-AM hydrolysis. However, given the fact that clopidogrel-AM shares a high degree of similarity in its chemical structure with clopidogrel and 2-oxo-clopidogrel, we anticipate that G143E and D260fs are loss-of-function variants for clopidogrel-AM as well.
Native expression of major drug metabolizing enzymes including CYP enzymes and CES1 are undetectable in the parent HEK293 cells which were used to create the transfected cell lines (Bouman et al., 2011) . Therefore, the cells serve as an excellent model to study the effect of genetic variation on the function of CES1. However, the oxidative intermediate and active (Levine et al., 2011; Wright et al., 2011) . However, numerous investigations have revealed a broad interindividual variability in response profiles to clopidogrel therapy. Importantly, this has shown to have prognostic implications (Angiolillo et al., 2007) . In particular, patients with reduced clopidogrel mediated antiplatelet effects who persist with high on-treatment platelet reactivity (also known as "poor responders") have an increased risk of recurrent ischemic events, including stent thrombosis, while patients with enhanced clopidogrel mediated antiplatelet effects who have low on-treatment platelet reactivity (also known as "hyper responders") have an increased risk of bleeding complications (Ferreiro et al., 2010) . Enormous efforts have been made to determine the causes of this marked variability of outcomes. Genetic polymorphisms of drug metabolizing enzymes, such as CYP2C19, are considered to be an important contributing factor to varied clopidogrel treatment outcomes. However, all biomarkers currently used for the prediction of clopidogrel response including CYP2C19 genotypes can only explain a very small portion of the observed variability. Given the very broad application in clinical practice of this pivotal antiplatelet agent, defining determinants of variability in clopidogrel response is critical and may have important therapeutic implications. Our present study suggests that CES1 can markedly affect clopidogrel metabolism and activation, indicating functional CES1 SNPs may be associated with higher plasma concentrations of clopidogrel-AM and enhanced antiplatelet activity. In fact, while this manuscript was under preparation, Lewis et
al reported that the CES1A1 variant G143E discovered in our laboratory (Zhu et al., 2008) was associated with significantly increased plasma concentrations of clopidogrel-AM and greater clopidogrel response in participants of the Pharmacogenomics of Anti-Platelet Intervention (PAPI) study (n=566) and in 350 patients with coronary heart disease (Lewis et al., 2012) . This clinical observation is fully in agreement with our in vitro data of the present study.
Beyond CES1 genetic polymorphisms, CES1 mediated drug-drug interactions have the potential to influence clopidogrel activation and the ensuring pharmacological effect as well. Additional clinical investigations are needed to evaluate the effect of CES1-mediated drug-drug interactions on therapeutic outcomes of clopidogrel, and whether CES1 genetic variants can be utilized as a biomarker to predict clopidogrel response, and individualize clopidogrel doses in clinical practice. 
